- Gregor Siebert made Head of Marketing and Sales
- Focus to be on international sales partnerships
- First important milestone in the restructuring of curasan
curasan AG (ISIN: DE0005494538), a leading specialist for medical devices in the field of bone and tissue regeneration, announced a strategically important change in HR within the group. Gregor Siebert, a manager with global experience in the pharmaceutical industry, will be Head of Marketing and Sales with immediate effect.
Siebert began his career in the pharmaceutical industry in 1985 at Abbott Germany, where he was responsible for the segments of hospital products and medical nutrition, having held various positions in marketing and sales in his role as Divisional Manager. After successfully promoting the expansion of the commercial organisation and the introduction of product innovations in managerial positions at Hikma Pharmaceuticals from 2004, he was Vice President of Hospital Europe at Pfizer responsible for the optimisation of the value adding processes that began with effect from 2010 in the European hospital business and for generic products. Finally, he managed the global pharmaceutical business at GL Pharma, Austria as Head of Marketing and Sales since 2014.
Michael Schlenk, the new CEO of curasan AG since the end of 2014, sees major opportunities in this appointment for a paradigm shift within the group: "With Gregor Siebert, we are making significant gains in marketing and sales skills on a global level in the healthcare market. With the restructuring that has just begun at curasan, a key role is being assigned to the Marketing & Sales Division. The aim is to expand our sales network and to refocus on our marketing with a view to offering a wider platform to the indisputably pioneering products of curasan for the next spurt of growth."
The new Head of Marketing and Sales also expects an exciting set-up: "curasan has been active in the market for almost thirty years and has a wide range of approved high-tech innovations and a number of patents to its name. I am very happy and look forward to the opportunity of charting out new paths of success at curasan with my many years of experience and through working closely together with the new management team."
The company shall announce further details on the strategy for the development of curasan AG over the next 24 months during the course of the forthcoming Annual General Meeting on June 25th, 2015.
About curasan AG:
curasan AG specialises in medical products for bone and tissue regeneration in the segment of regenerative medicine. It has set up a ground-breaking product pipeline of synthetic substitution and regeneration materials. Numerous patents and a comprehensive list of scientific documentation have established the clinical success of the products and the highly innovative strength of curasan AG. The list of users include surgically active dentists, implantologists and oral, maxillary and dentofacial surgeons, as well as orthopaedics, traumatologists and spinal column surgeons. The company is listed in the General Standard at the Frankfurt Stock Exchange (ISIN: DE 000 549 453 8).
www.curasan.de
Contact:
curasan AG
Andrea Weidner
Tel. +49 6027 40900-51
Fax +49 6027 40900-39
andrea.weidner@curasan.de
www.curasan.de
fr financial relations gmbh
Jörn Gleisner
Tel. +49 6172 27159-20
Fax +49 6172 27159-69
j.gleisner@finanical-relations.de
